Personalis (NASDAQ:PSNL) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Personalis (NASDAQ:PSNL) had its price target boosted by equities research analysts at Morgan Stanley from $9.00 to $13.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective indicates a potential downside of 7.60% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the company. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research lowered their price target on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Monday, May 11th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Personalis presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

Personalis Trading Down 4.0%

PSNL stock opened at $14.07 on Thursday. The firm has a market capitalization of $1.47 billion, a PE ratio of -13.79 and a beta of 2.24. The business’s 50 day simple moving average is $9.99 and its 200 day simple moving average is $8.65. Personalis has a 1-year low of $3.84 and a 1-year high of $15.36.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). Personalis had a negative net margin of 148.11% and a negative return on equity of 43.52%. The company had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. As a group, sell-side analysts predict that Personalis will post -1.06 EPS for the current fiscal year.

Insider Buying and Selling at Personalis

In other Personalis news, CFO Aaron Tachibana sold 51,251 shares of Personalis stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the transaction, the chief financial officer directly owned 198,833 shares of the company’s stock, valued at $2,620,618.94. This trade represents a 20.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of Personalis stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the sale, the chief executive officer owned 235,986 shares of the company’s stock, valued at approximately $3,103,215.90. This trade represents a 29.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 435,032 shares of company stock valued at $5,599,929 in the last 90 days. Company insiders own 4.20% of the company’s stock.

Institutional Investors Weigh In On Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd grew its position in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock valued at $27,000 after buying an additional 1,479 shares during the period. Legal & General Group Plc purchased a new stake in shares of Personalis during the 2nd quarter valued at approximately $30,000. International Assets Investment Management LLC acquired a new position in shares of Personalis in the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets grew its stake in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock valued at $42,000 after buying an additional 5,177 shares in the last quarter. Finally, Focus Partners Wealth purchased a new position in Personalis during the 1st quarter valued at about $47,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.